Scandinavian journal of gastroenterology · 2026
Predictive value of iron deficiency anaemia on the one-year disease course in inflammatory bowel disease patients in clinical and biochemical remission.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Resál Tamás, Lupas Dániel, Keresztes Csilla, Bacsur Péter, Pápista Máté, Beke Nóra, Bálint Anita, Tóth Tibor, Bor Renáta, Fábián Anna, Farkas Bernadett, Csefkó Klára, Szepes Zoltán, Farkas Klaudia, Varga Márta, Molnár Tamás
Аннотация
BACKGROUND: Iron deficiency anaemia (IDA) is a common comorbidity in inflammatory bowel diseases (IBD). It is hypothesized that IDA result in poorer outcomes also in patients with remission.
METHODS: This multicenter retrospective real-life cohort study assessed the predictive value of IDA in inactive IBD patients. IDA was defined as ferritin <30 μg/mL and transferrin saturation <20% with the presence of anaemia. Primary outcome was the need of hospitalization/abdominal surgery. Secondary outcome was minor complications, defined as new treatment admission and/or dose escalation during the follow-up period.
RESULTS: In total, 708 patients (median age:43.1 years [IQR: 32.3-49.6]; male/female ratio:332/379; CD:397, UC:311; IDA/non-IDA 85/623) were enrolled. The presence of IDA increased the risk of minor complications (OR:1.9) and hospitalization/abdominal surgery (OR:2.8).
CONCLUSION: IDA predicts the risk of relapse in patients with clinical and biochemical remission in the outpatient setting. IDA may help to identify underlying disease activity in patients with clinical and biochemical remission in time, therefore, in these cases we suggest further workups and to consider treatment modification.
METHODS: This multicenter retrospective real-life cohort study assessed the predictive value of IDA in inactive IBD patients. IDA was defined as ferritin <30 μg/mL and transferrin saturation <20% with the presence of anaemia. Primary outcome was the need of hospitalization/abdominal surgery. Secondary outcome was minor complications, defined as new treatment admission and/or dose escalation during the follow-up period.
RESULTS: In total, 708 patients (median age:43.1 years [IQR: 32.3-49.6]; male/female ratio:332/379; CD:397, UC:311; IDA/non-IDA 85/623) were enrolled. The presence of IDA increased the risk of minor complications (OR:1.9) and hospitalization/abdominal surgery (OR:2.8).
CONCLUSION: IDA predicts the risk of relapse in patients with clinical and biochemical remission in the outpatient setting. IDA may help to identify underlying disease activity in patients with clinical and biochemical remission in time, therefore, in these cases we suggest further workups and to consider treatment modification.